Menu
Search
|

Menu

Close
X

Brainstorm Cell Therapuetics Inc BCLI.OQ (NASDAQ Stock Exchange Capital Market)

4.23 USD
-- (--)
As of Jul 13
chart
Previous Close 4.23
Open --
Volume --
3m Avg Volume 24,494
Today’s High --
Today’s Low --
52 Week High 5.34
52 Week Low 2.88
Shares Outstanding (mil) 19.11
Market Capitalization (mil) 80.84
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.121
FY17
-0.265
FY16
-0.267
FY15
-0.462
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.20
Price to Sales (TTM)
vs sector
--
8.07
Price to Book (MRQ)
vs sector
21.09
4.28
Price to Cash Flow (TTM)
vs sector
--
22.38
Total Debt to Equity (MRQ)
vs sector
0.00
17.39
LT Debt to Equity (MRQ)
vs sector
0.00
13.21
Return on Investment (TTM)
vs sector
-90.50
13.23
Return on Equity (TTM)
vs sector
-90.50
15.28

EXECUTIVE LEADERSHIP

Irit Arbel
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Chaim Lebovits
President, Chief Executive Officer, Since 2015
Salary: $282,500.00
Bonus: $141,250.00
Eyal Rubin
Chief Financial Officer, Treasurer, Since 2017
Salary: --
Bonus: --
Ralph Kern
Chief Operating Officer and Chief Medical Officer, Since 2017
Salary: --
Bonus: --
Uri Yablonka
Executive Vice President, Chief Business Officer, Director, Since 2017
Salary: $100,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1745 Broadway Fl 17
NEW YORK   NY   10019-4642

Phone: +1201.4880460

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.

SPONSORED STORIES